Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia

References

• Ohno R, Kobayashi T, Tanimoto M, et al Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group. Cancer 1993;71:3888–3895.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Miyawaki S, Tanimoto M, et al Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. J Clin Oncol 1996;14:204–213.
   PubMed Web of Science ®Google Scholar
• Miyawaki S, Tanimoto M, Kobayashi T, et al No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group. Int J Hematol 1999;70:97–104.
   PubMed Web of Science ®Google Scholar
• Büchner T, Hiddemann W, Berdel WE, et al 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 2003;21:4496–4504.
   PubMed Web of Science ®Google Scholar
• Moore JO, George SL, Dodge RK, et al Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood 2005;105:3420–3427.
   PubMed Web of Science ®Google Scholar
• Cassileth PA, Harrington DP, Hines JD, et al Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 1988;6:583–587.
   PubMed Web of Science ®Google Scholar
• Inoue K, Sugiyama H, Ogawa H, et al WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071–3079.
   PubMed Web of Science ®Google Scholar
• Østergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. Br J Haematol 2004;125:590–600.
   PubMed Web of Science ®Google Scholar
• Weisser M, Kern W, Rauhut S, et al Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 2005;19:1416–1423.
   PubMed Web of Science ®Google Scholar
• Lapillonne H, Renneville A, Auvrignon A, et al High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 2006;24:1507–1515.
   PubMed Web of Science ®Google Scholar
• Ommen HB, Nyvold CG, Braendstrup K, et al Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol 2008;141:782–791.
   PubMed Web of Science ®Google Scholar
• Cilloni D, Renneville A, Hermitte F, et al Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009;27:5195–5201.
   PubMed Web of Science ®Google Scholar
• Miyawaki S, Emi N, Mitani K, et al Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan. Rinsho Ketsueki 2005;46:1279–1287.
   PubMedGoogle Scholar
• Miyawaki S, Ohtake S, Fujisawa S, et al Long-term follow-up of the randomized JALSG AML 201 study comparing high dose Ara-C therapy with conventional consolidation therapy in adult acute myeloid leukemia (AML). Blood 2008;112(Suppl. 1): Abstract 135.
   Google Scholar
• Osumi K, Fukui T, Kiyoi H, et al Rapid screening of leukemia fusion transcripts in acute leukemia by real-time PCR. Leuk Lymphoma 2002;43:2291–2299.
   PubMed Web of Science ®Google Scholar
• Elmaagacli AH, Beelen DW, Trenschel R, Schaefer UW. The detection of WT-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 2000;25:91–96.
   PubMed Web of Science ®Google Scholar
• Gaiger A, Schmid D, Heinze G, et al Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia 1998;12:1886–1894.
   PubMed Web of Science ®Google Scholar
• Cilloni D, Messa F, Arruga F, et al Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica 2008;93:921–924.
   PubMed Web of Science ®Google Scholar
• Nowakowska-Kopera A, Sacha T, Florek I, Zawada M, Czekalska S, Skotnicki AB. Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia. Leuk Lymphoma 2009;50:1326–1332.
   PubMed Web of Science ®Google Scholar
• Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood. 1996;88:756.
   PubMed Web of Science ®Google Scholar